1 173

Cited 0 times in

Non-bacterial infections in Asian patients treated with alemtuzumab:a retrospective study of the Asian Lymphoma Study Group

Authors
 Seok Jin Kim  ;  Joon Ho Moon  ;  Hawk Kim  ;  Jin Seok Kim  ;  Yu Yan Hwang  ;  Tanin Intragumtornchai  ;  Surapol Issaragrisil  ;  Jae Yong Kwak  ;  Je Jung Lee  ;  Jong Ho Won  ;  Arry Harryanto Reksodiputro  ;  Soon Thye Lim  ;  Ann-Lii Cheng  ;  Won Seog Kim  ;  Yok Lam Kwong 
Citation
 LEUKEMIA & LYMPHOMA, Vol.53(8) : 1515-1524, 2012 
Journal Title
 LEUKEMIA & LYMPHOMA 
ISSN
 1042-8194 
Issue Date
2012
MeSH
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Alemtuzumab ; Antibodies, Monoclonal, Humanized/adverse effects* ; Antineoplastic Agents/adverse effects ; Asia ; Child ; Cytomegalovirus Infections/complications ; Female ; Herpes Zoster/complications ; Humans ; Lymphoma/complications ; Lymphoma/drug therapy* ; Male ; Middle Aged ; Mycoses/complications ; Retrospective Studies ; Salvage Therapy/methods ; Stem Cell Transplantation/methods ; Transplantation Conditioning/methods ; Transplantation, Homologous/methods
Keywords
Alemtuzumab ; infection ; prophylaxis
Abstract
This retrospective study concerns non-bacterial infections in Asian patients receiving alemtuzumab. The clinical data of 182 patients treated with alemtuzumab alone or alemtuzumab-containing chemotherapy between the years 2003 and 2009 was collected from six Asian countries. Alemtuzumab was used in the setting of frontline (n =48) or salvage (n =90) treatment, and as a part of the conditioning regimen for allogeneic stem cell transplant (n =44). Reactivation of cytomegalovirus (66/182) and varicella zoster virus (25/182), and fungal infection (31/182) including invasive pulmonary aspergillosis, were the most common infectious complications in this retrospective analysis. Thus, we recommend routine prophylaxis with valganciclovir and itraconazole, especially when alemtuzumab is used in the conditioning regimen for allogeneic stem cell transplant. Pneumocystis jirovecii pneumonia (PJP) was found in four patients (3%, 4/122) receiving alemtuzumab as conditioning for stem cell transplant or salvage treatment. Three cases of hepatitis B virus reactivation were found in antigen-negative patients, and 16 cases of tuberculosis were observed. Infection is the major complication of alemtuzumab therapy, and these infectious complications are potentially severe and life-threatening. Based on our retrospective analysis, we have constructed a guideline for antimicrobial prophylaxis in Asian patients receiving alemtuzumab therapy.
Full Text
http://informahealthcare.com/doi/abs/10.3109/10428194.2012.659735
DOI
22273250
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/91393
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse